GLP-1 drugs cut heart failure deaths by 42% and may protect against Alzheimer's
GLP-1 drugs cut heart failure deaths by 42% and may protect against Alzheimer's
This week brought a flood of research on GLP-1 drugs like semaglutide and tirzepatide, revealing benefits that go far beyond blood sugar control. From protecting hearts to potentially preventing Alzheimer's, these medications are reshaping how we think about treating multiple diseases at once.
🫀 GLP-1 Drugs Slash Heart Failure Deaths by Over 40%
A massive study of 69,590 patients with heart failure and preserved ejection fraction found that GLP-1 drugs dramatically reduce serious outcomes:
Semaglutide cut the risk of heart failure hospitalization or death by 42% (hazard ratio 0.58)
Tirzepatide performed even better with a 58% risk reduction (hazard ratio 0.42)
Both drugs showed consistent benefits across different patient groups, with no major safety concerns
Why this matters: Heart failure with preserved ejection fraction affects millions and has limited treatment options. These results suggest GLP-1 drugs could become a cornerstone therapy for this challenging condition, potentially preventing thousands of hospitalizations and deaths annually.
Key Findings
🧠 GLP-1 Drugs May Protect Against Alzheimer's Disease
Large-scale real-world data revealed that both GLP-1 receptor agonists and SGLT-2 inhibitors significantly reduced Alzheimer's risk compared to other diabetes medications. GLP-1 drugs showed up to 31% lower risk (hazard ratio ≤ 0.69), while SGLT-2 inhibitors demonstrated up to 33% lower risk (hazard ratio ≤ 0.67). The protective effects were seen with multiple drugs in each class, including semaglutide, liraglutide, and others.
🧬 Semaglutide Helps Schizophrenia Patients Without Harming Mental Health
In 154 patients with schizophrenia taking antipsychotic medications, 30 weeks of semaglutide treatment delivered impressive results without psychiatric side effects. Patients lost an average of 9.21 kg, reduced their diabetes risk significantly (81% achieved normal blood sugar vs 19% on placebo), and improved their physical quality of life by 3.75 points. Crucially, there was no worsening of schizophrenia symptoms or mental health scores.
💊 Meta-Analysis Confirms No Suicide Risk from GLP-1 Drugs
Analysis of 25 randomized controlled trials found no significant association between GLP-1 receptor agonists and suicidal behavior (risk ratio 0.84, not statistically significant). This held true across different patient populations (diabetes, obesity, adults, adolescents), different types of suicidal behavior (ideation, attempts, completed suicide), and all GLP-1 drugs tested including semaglutide, liraglutide, and dulaglutide.
🏥 Combination Therapy Reduces Death Risk by 83%
In 138,397 patients with diabetes and cardiovascular disease, using both SGLT-2 inhibitors and GLP-1 receptor agonists together showed remarkable benefits. The combination reduced all-cause mortality by 83% (hazard ratio 0.17) compared to patients receiving neither medication. Even individual drugs showed substantial benefits: SGLT-2 inhibitors alone reduced death risk by 72%, while GLP-1 drugs alone reduced it by 61%.
🔬 Tirzepatide Shows Promise for Parkinson's Disease
In mouse models of Parkinson's disease, tirzepatide demonstrated neuroprotective effects by improving mitochondrial function and energy production. The dual GLP-1/GIP receptor agonist reduced harmful mitochondrial fragmentation, enhanced cellular cleanup processes (mitophagy), and restored ATP energy levels. Importantly, tirzepatide showed comparable effectiveness to semaglutide and the standard Parkinson's treatment levodopa, but at one-third the dose.
📊 75,000+ Heart Events Could Be Prevented Annually in the US
Based on SUSTAIN-6 trial results, researchers calculated that if all eligible US adults with type 2 diabetes received semaglutide, approximately 75,681 major cardiovascular events could be prevented each year. The analysis found 6.9 million Americans would meet the trial's eligibility criteria, though the real-world population was more diverse than the original trial participants, including more women and Black patients.
Implications
This week's research paints a picture of GLP-1 drugs as remarkably versatile medications that extend far beyond their original diabetes indication. The convergent evidence suggests these drugs may work through fundamental biological pathways that protect multiple organ systems simultaneously—offering a rare example of treatments that could meaningfully impact several major diseases at once.
Studies in this issue
Primary sources used for this newsletter.
- Semaglutide and Tirzepatide in Patients with Heart Failure and Normal Pumping Functionmain storyJAMA2025-08-31PMID 40886075
- How SGLT2 inhibitors and GLP-1 receptor agonists relate to death rates in diabetic patients with heart diseasekey findingCardiovascular diabetology2025-08-31PMID 40887578
- Number of U.S. adults with type 2 diabetes who could benefit from semaglutide to prevent heart diseasekey findingDiabetes & vascular disease research2025-09-05PMID 40908778
- Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as possible treatments for Alzheimer's diseasekey findingAlzheimer's & dementia : the journal of the Alzheimer's Association2025-09-03PMID 40898408
- GLP-1 Receptor Agonists and Their Link to Suicide Behavior: A Review of Controlled Trialskey findingJournal of diabetes2025-09-01PMID 40887719
- Semaglutide treatment in people with schizophrenia on antipsychotics who have prediabetes and obesitykey findingJAMA psychiatry2025-09-03PMID 40900607
- Tirzepatide, a drug activating two gut hormones, may improve Parkinson’s symptoms in mice by supporting mitochondrial healthkey findingInternational immunopharmacology2025-08-31PMID 40886502
Continue reading
All GLP-1 Therapies issuesGet the next GLP-1 Therapies issue
Seven papers, once a week. Free.